Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.84 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.84 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP4 | P49662 | 1/20 | 0.42 |
| ▸ | CASP5 | P51878 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | SCN11A | Q9UI33 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3611455 | 0.97 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL1564103 | 0.97 | CHRM5 (0.90) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL14473007 | 0.94 | — | — | |
| SCHEMBL1827882 | 0.94 | CHRM5 (0.94) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL1515104 | 0.92 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL20643257 | 0.92 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL3439882 | 0.92 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL19575409 | 0.92 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL30340995 | 0.92 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 | |
| SCHEMBL18361231 | 0.92 | CHRM5 (1.00) | CHRM5ADRA2CACHESMN1; SMN2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | disclosed |
| US-11185374-B2 | Apparatus and methods relating to intravascular positioning of distal end of catheter | C. R. BARD, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210145974-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | YALE UNIVERSITY | 2021-05-20 | — | — | US | disclosed |
| US-20190110844-A1 | Apparatus And Methods Relating To Intravascular Positioning Of Distal End Of Catheter | BARD INC C R (US) | 2019-04-18 | — | — | US | disclosed |
| EP-3027587-B1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE LABOR DR (ES) | 2018-07-25 | — | — | EP | disclosed |
| EP-2170875-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885 |
| US-20210145974-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR3B | CHRM5 1306/4885ADRA2C 2024/4885ACHE 3555/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | CHRM5 4105/4885ADRA2C 2057/4885ACHE 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.